Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients. The therapy ...

The market for radioligand therapies (RLT), also known as radiopharmaceuticals, a relatively new kind of treatment, is ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...